Barbara's Beat: Concentrated MOTRIN® Infants’ Drops Original Berry Flavor recalled due to plastic hazard
Sam's Club

Tuesday, September 10, 2013

Concentrated MOTRIN® Infants’ Drops Original Berry Flavor recalled due to plastic hazard


McNeil Consumer Healthcare Division is voluntarily recalling three lots, approximately 200,000 bottles, of Concentrated MOTRIN® Infants’ Drops Original Berry Flavor 1/2 fl oz bottles distributed in the United States. 


This recall is being conducted with the knowledge of the U.S. Food and Drug Administration (FDA). McNeil is asking retailers to remove the affected lots from store shelves, and is asking consumers to stop using and dispose of any product they may have that is included in this recall. 

FULL RECALLED PRODUCT LIST:
Product Lot # UPC Code Case UPC Code
Concentrated MOTRIN® Infants’ Drops
Original Berry Flavor 1/2 fl oz bottles

NDC 50580-100-18
DCB3T01 300450524157 30300450524158
DDB4R01
DDB4S01

After releasing these three lots of Concentrated MOTRIN® Infants’ Drops Original Berry Flavor 1/2 fl oz into the market, tiny plastic particles (approximately 1 mm in size or about the size of a poppy seed) were identified in a different product lot during manufacturing. This lot was not released to the market. 

It was determined that the particles originated in a shipment from a third party supplier of ibuprofen, the active ingredient in Concentrated MOTRIN® Infants’ Drops Original Berry Flavor 1/2 fl oz. McNeil is voluntarily recalling the three lots released to the market made with the same batch of active ingredient as a precaution. 

McNeil has worked with the third party to ensure that corrective measures are in place and effective. The potential for adverse medical events related to the reason for this recall is not likely. 

Concentrated Infants’ MOTRIN® Drops Dye-Free Berry Flavor 1 fl oz is not included in this recall. Children’s or Adult MOTRIN® products are not included in this recall.


Adverse events that may be related to the use of this product may be reported to U.S. Food and Drug Administration’s (FDA) MedWatch Adverse Event Reporting Program either online, by regular mail or by fax:

No comments: